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aim: The aim was to study acquisition and persistence of carbapenemase-producing 
Enterobacteriaceae (CPE) among travelers. Materials & methods: Stools from 2001 travelers 
and 215 nontraveling household members, collected before and immediately post-travel as 
well as 1, 3, 6 and 12 months upon return, were screened for CPE. Results: Five travelers, all 
visiting Asia outside the Indian subcontinent, acquired CPE. One traveler persistently carried 
the same OXA-244 CPE up to 6 months post-travel. Three months after travel, her co-traveling 
spouse also became positive for this OXA-244 CPE strain, suggesting clonal transmission 
within this household. conclusion: Acquisition of CPE is not restricted to travelers to the 
Indian subcontinent and/or to travelers seeking healthcare during travel and can persist up 
to at least 6 months post-travel.
First draft submitted: 8 October 2015; Accepted for publication: 21 April 2016;  
Published online: 30 June 2016
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The Indian subcontinent has been identified as an important reservoir of carbapenemase-produc-
ing Enterobacteriaceae (CPE). Indeed, acquisition of CPE during travel to India has recently been 
reported, illustrating the risk of further global spread by travelers to this CPE-endemic region [1]. 
However, acquisition of CPE in healthy travelers to Asian regions other than the Indian subconti-
nent is suggested but has not been reported from prospective studies thus far. There are a number of 
prospective studies on acquisition of extended-spectrum β-lactamase-producing Enterobacteriaceae 
(ESBL-E) and CPE in healthy travelers [1–10]. Except for the above-mentioned study on CPE acquisi-
tion in travelers to India [1], none of these studies identified subjects with CPE acquisition during travel.
Within the context of a large-scale prospective cohort of healthy travelers, the COMBAT study, we 
aimed to determine CPE acquisition, persistence of colonization and potential onward transmission.
Materials & methods
●● Design & data collection
As part of the COMBAT study (ClinicalTrials.gov identifier: NCT01676974), a multicenter longi-
tudinal cohort of healthy travelers (n = 2001) and their nontraveling household members (n = 215) 
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was followed. Participants were recruited within 
a period of 1 year, from November 2012 until 
November 2013 at the outpatient clinics run by 
the Academic Medical Center (Amsterdam, The 
Netherlands), Havenziekenhuis (Rotterdam, The 
Netherlands) and Maastricht University Medical 
Center/Public Health Service South Limburg 
(Maastricht, The Netherlands). Adult (≥18 years) 
travelers visiting one of the above-stated travel clin-
ics, traveling abroad for a minimum of 1 week to a 
maximum of 3 months were eligible for participa-
tion. Minors (<18 years) and incapacitated subjects 
are excluded from this study. No r estriction was 
applied with respect to travel destination.
Fecal samples (Fecal Swab®; Copan, Brescia, 
Italy) were collected before, immediately after 
(within 1–2 weeks) and 1 month after return 
from all participants. Follow-up fecal samples 
were collected 3, 6 and 12 months after return 
from travelers (and their household members) 
who acquired extended-spectrum β-lactamase-
producing Enterobacteriaceae (ESBL-E) 
and/or CPE. Ethical approval was obtained by 
the Medical Ethical Committee of Maastricht 
University Medical Center (study number: 
METC 12-4-093). A full description of the 
study design has been published elsewhere [11].
●● Microbiological methods
Fecal samples were enriched overnight at 35°C 
in TSB with vancomycin (50 mg/l) to prevent 
overgrowth of Gram-positive bacteria [12]. Ten 
microliters were inoculated on chromID® ESBL 
agar (bioMérieux, Marcy l’Etoile, France) and 
incubated overnight at 35°C. Screening with this 
cefpodoxime-containing agar aims at maximum 
detection of ESBL-E. However some CPE, such 
as those producing OXA-48-like β-lactamases 
not co-producing an ESBL, remain susceptible 
and can be missed using this agar [13]. To see 
what the proportion of EBSL-negative, OXA-
48-positive CPE was in our cohort, a substudy 
was held from August until November 2013. In 
total, 500 consecutive post-travel samples were 
additionally screened for OXA-48 CPE using 
chromID OXA-48 agar. All colonies of differ-
ent morphologies growing on any of these two 
agars were characterized to the species level using 
MALDI-TOF (Bruker, London, UK). Minimum 
inhibitory concentrations (MICs) were measured 
for all Enterobacteriaceae by the use of the Vitek 
2 system (bioMérieux, Marcy l’Etoile, France).
Phenotypic confirmation of ESBL production 
was performed by the combination disk diffusion 
test according to current national Dutch guide-
lines [14]. Isolates with MICs for imipenem >1 
mg/l or for meropenem >0.25 mg/l, confirmed 
with E-test (bioMérieux), were considered pos-
sible carbapenemase producers [14] and genotypi-
cally characterized. In case a CPE was cultured 
from the post-travel sample (either from the ESBL 
or OXA-48 agar) specific PCR for the detected 
carbapenemase gene was performed on fecal 
metagenomic DNA of the pretravel sample. All 
CPE suspected isolates were screened for the pres-
ence of multiple classes of ESBL and carbapene-
mase genes using microarray (Identibac® AMR08; 
Alere Technologies GmbH, Jena, Germany) [15,16]. 
Targeted PCR and DNA sequencing of the 
PCR-amplicons was performed with primers as 
described previously [15,17–23] and in-house prim-
ers. The underlined nucleotide from the IMI 
primer 5́ -CAAAGCAAATGAACGATTTC-3´ 
was modified from [23]. DNA was extracted as 
described by Anjum et al. [15]. The lysate contain-
ing the crude DNA was used for biotin la beling 
and PCR.
All acquired carbapenemase-producing 
Escherichia coli and Klebsiella pneumoniae isolates 
from post-travel samples were further analyzed 
with multilocus sequence typing (MLST) [24,25] 
and sequence types (ST) were assigned by query-
ing the respective MLST databases for E. coli [26] 
and K. pneumoniae [27].
To determine persistence of carriage and 
clonal transmission, amplification fragment 
length polymorphism (AFLP) [28] was assayed 
for all consecutive CPE isolates of the travelers 
and their household members.
Results
More than half of all included travelers visited 
destinations in Asia (n = 1016/2001, 50.8%), 
while Africa was visited by 633 travelers 
(31.6%). America (mainly South and Central 
America), Europe and Oceania were visited by 
326 (16.3%), 21 (1.0%) and 5 (0.2%) travelers, 
respectively.
Prior to travel, one participant was carrying an 
OXA-48-producing E. coli and as such excluded 
from subsequent analysis. This 47-year-old 
healthy male subject had no travel history in the 
previous 12 months, but had been admitted to 
a Dutch hospital and treated with a zithromycin 
within the preceding 3 months.
In five travelers, CPE was detected in speci-
mens collected immediately upon return. Specific 
PCR for the detected carbapenemase-encoding 
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gene on fecal metagenomic DNA of the pretravel 
sample was negative in all five cases. Subject- 
and travel-related characteristics of the travel-
ers who acquired CPE during travel, as well as 
the molecular characteristics and dynamics over 
time of acquired CPE i solates, are s ummarized 
in table 1.
Out of the five travelers who acquired CPE, 
none had sought medical care during their 
travel, all but one (subject 3) reported diarrhea 
during travel and one traveler (subject 5) had 
used broad-spectrum antibiotics (table 1). This 
traveler used an oral drug called Disento for com-
plaints of watery diarrhea during travel (a mix 
of quinoline, aminoglycoside, nitrofuran and 
sulfonamide).
Out of the acquired CPEs, three isolates were 
E. coli of various sequence types and encoding 
different carbapenemase genes, one was an 
bla
OXA-48
-encoding ST363 K. pneumoniae and 




Similar to the previous report by Ruppé et al. [1], 
carriage of acquired CPE was of limited duration 
in three of our travelers, in whom CPE could 
not be detected 1 month after return from travel 
(table 1). However, in one traveler, CPE carriage 
persisted at least 1 month and in another traveler 
(subject 2a), an OXA-244-producing E. coli iso-
late persisted for at least 6 months after return, as 
evidenced by similar AFLP patterns of isolates in 
follow-up specimens (Figure 1). Three months after 
travel, an OXA-244 E. coli isolate with a similar 
AFLP pattern was isolated from a fecal sample 
collected from her spouse and travel companion 
(subject 2b; table 1 & Figure 1). As all other fecal 
specimens from this subject were CPE negative, 
this strongly suggests post-travel acquisition of 
the same bacterium through transmission from 
his wife.
Discussion
Our report underscores that CPE are indeed 
acquired during travel by healthy travelers in the 
absence of exposure to local healthcare during 
travel. Importantly, our observations also indicate 
that a risk of such acquisition during travel is not 
limited to travelers to the Indian subcontinent. 
In fact, none of 119 travelers in our cohort who 
traveled to India had acquired CPE. Instead, 
CPE acquisition was observed in five study par-
ticipants who traveled to Europe and countries 
in south-eastern, eastern and western Asian, 
i ncluding two out of 23 visitors to Myanmar.
The low prevalence of CPE in the pretravel 
samples from our study (one of 2001 subjects was 
positive for CPE) is consistent with the very low 
background carriage of CPE in the Dutch com-
munity as described previously. In two studies 
on the prevalence and molecular characteristics 
of ESBL-E in the Dutch community, conducted 
in 2010 and 2011 and including 720 and 1033 
subjects, respectively, no CPE or carbapenemase-
encoding genes were found [29,30]. Moreover, 
the prevalence of carbapenemase resistance in 
clinical isolates in The Netherlands was only 
0.01% for E. coli and 0.15% for K. pneumoniae 
in 2013–2014 [31].
One traveler to Myanmar acquired an 
E. c loacae complex isolate harboring an bla
IMI-2
 
gene. The IMI β-lactamases are a relatively 
uncommon group of carbapenemases. They are 
sporadically found in clinical isolates and envi-
ronmental isolates from rivers in the USA [20] 
and in clinical isolates from China [32] and 
France [33]. Acquisition of IMI carbapenemases 
in travelers has not been described yet. This 
acquisition shows that travel might not only play 
a role in the spread of more common OXA-48-
like and NDM-carbapenemases, but also of rarer 
p lasmid-encoded carbapenemases such as IMI-2.
Another traveler to Myanmar acquired an 
ST162 E. coli isolate carrying an bla
NDM-7
 gene. 
Although data on the prevalence of antimicrobial 
resistance in Myanmar are very limited, it is inter-
esting to note that the first NDM-7 E. coli was 
recovered in France from urine of a female patient 
who also traveled to Myanmar [34]. Concordantly 
with the isolate retrieved in our study, this iso-
late also harbored a bla
CTX-M-15
 ESBL gene, but 
belonged to a different sequence type (ST167).
A second bla
NDM
 gene was acquired by a 
traveler when traveling throughout south-east-
ern and eastern Asia. NDM-producers are con-
sidered to be endemic in India and Pakistan [35], 
but likely have spread from the Indian subcon-
tinent to neighboring countries and through-
out Asia as ref lected by the acquisition of 
bla
NDM
 genes in the two travelers that traveled 
outside these countries and confirmed by pub-
lications on the emergence of NDM-producing 
Enterobacteriaceae in Thailand [36].
One of the 270 travelers that visited Indonesia 
acquired a CPE: an OXA-244 positive E. coli 
isolate belonging to ST38. OXA-244 is an 
OXA-48-like β-lactamase that exhibits weak 
carbapenemase activity and which differs by 
a single amino acid substitution from classical 
Future Microbiol. (2016) 11(7)860
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OXA-48 [37]. ST38-type E. coli isolates harbor-
ing a classical bla
OXA-48
 gene have previously 
been recovered from Lebanon, Egypt, Turkey, 
Switzerland and France [38–41]. More recently, 
the OXA-48-like variant OXA-244 was also 
identified in an ST38 E. coli isolated from a hos-
pitalized patient in France without any travel his-
tory [42]. To our knowledge, there are no reports 
of OXA-48-like harboring Enterobacteriaceae 
from Indonesia.
An OXA-48 harboring K. pneumoniae isolate 
was acquired by a traveler that visited Turkey and 
Greece. For many years, almost all the reports 
of OXA-48-producers remained from patients 
hospitalized in Turkey or from patients with a 
link to Turkey [21]. The endemicity of OXA-48 
in this country has most likely resulted to the 
acquisition in this traveler, as Greece is known 
as an important reservoir for KPC, but not for 
OXA-48 [35].
Household transmission of travel-acquired 
CPE between healthy subjects 2a and 2b was 
strongly suspected, although the possibility can-
not be fully excluded that subject 2b also acquired 
CPE during travel but that this remained unde-
tected in initial specimens. Possible household 
transmission from a documented carbapene-
mase-producing K. pneumoniae carrier – a female 
with amyotrophic lateral sclerosis that required 
mechanical ventilation and had been hospital-
ized in a tertiary hospital in the Tel Aviv area 
– to her spouse has previously been reported [43]. 
Another paper describes possible vertical or hori-
zontal transmission of an NDM-1-producing 
Enterobacter cloacae in an Australian newborn 
that did not travel overseas [44].
The COMBAT-study aimed at maximum 
detection of ESBL-E, which might have led to 
an underestimation of acquisition of OXA-48-
like β-lactamase producers. In our subset of 500 
travelers, one additional OXA-48 acquisition was 
found (subject 3). This indicates that likely only 
a few additional OXA-48 acquisitions would 
have been detected when all 2001 subjects would 
have been screened with OXA-48 agar.
Literature on antimicrobial resistance in 
resource-limited settings is infrequent thereby 
hampering the comparison between CPEs 
acquired by travelers and the local prevalence and 
molecular characteristics of CPEs at the travel des-
tination. However, travelers may act as a sentinel 
for emerging local resistance in developing coun-
tries like Indonesia and Myanmar as illustrated 
in this paper.
Future Microbiol. (2016) 11(7)862




 ●  Acquisition of carbapenemase-producing Enterobacteriaceae (CPE) in healthy travelers without local healthcare 
contact during travel has recently been described for travelers to India.
Results
 ●  This study reports acquisition of CPE in five travelers to Asia that did not travel across the Indian subcontinent.
 ●  None of these travelers had sought medical care during their travel, all but one reported diarrhea during travel and 
one traveler had used broad-spectrum antibiotics.
 ●  Persistence of colonization up to at least 6 months after return from travel was found for one traveler.
 ●  In one of the CPE-positive travelers evidence was found for clonal transmission of OXA-244 Escherichia coli to her spouse.
conclusion
 ●  Acquisition of CPE during travel is neither restricted to travelers to the Indian subcontinent nor to travelers seeking 
healthcare during travel.
 ●  Screening for CPE in patients who are admitted to healthcare facilities should be considered, not only after recent 
travel, but even several months after returning from high-risk countries.
conclusion & future perspective
In conclusion, the risk of acquisition of CPE 
during travel is not restricted to travelers to the 
Indian subcontinent and/or to travelers seek-
ing healthcare during travel and carriage of 
travel-acquired CPE can persist up to at least 
6 months after return from travel. Prolonged 
carriage obviously increases the risk of onward 
transmission and further spread of CPE. These 
observations deserve consideration by health-
care providers and public health professionals 
worldwide. Particularly in countries with low-
level prevalence of CPE, screening for CPE in 
patients who are admitted to healthcare facili-
ties should be considered, not only after recent 
travel, but even several months after returning 
from high-risk countries.
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